Patents by Inventor Carl R. Flannery

Carl R. Flannery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides encoding recombinant lubricin molecules and uses thereof
    Patent number: 8420793
    Abstract: Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: April 16, 2013
    Assignee: Pfizer Inc.
    Inventors: Carl R. Flannery, Christopher J. Corcoran, Bethany A. Freeman, Lisa A. Collins-Racie
  • Modified ADAMTS4 molecules and method of use thereof
    Patent number: 7118902
    Abstract: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: October 10, 2006
    Assignee: Wyeth
    Inventors: Christopher John Corcoran, Carl R. Flannery, Weilan Zeng, Lisa A. Racie, Thomas McDonagh, Bethany A. Freeman, Katy E. Georgiadis, Edward R. LaVallie
  • Aggrecanase molecules
    Patent number: 7078217
    Abstract: Novel aggrecanase proteins and the nucleotide sequences encoding them as well as processes for producing them are disclosed. Methods of identifying and developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: July 18, 2006
    Assignee: Wyeth
    Inventors: Christopher J. Corcoran, Michael J. Agostino, Edward R. LaVallie, Carl R. Flannery, Lisa A. Collins-Racie
  • Modified ADAMTS4 molecules and method of use thereof
    Publication number: 20040142863
    Abstract: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
    Type: Application
    Filed: July 29, 2003
    Publication date: July 22, 2004
    Applicant: WYETH
    Inventors: Christopher John Corcoran, Carl R. Flannery, Weilan Zeng, Lisa A. Racie, Thomas McDonagh, Bethany A. Freeman, Katy E. Georgiadis, Edward R. LaVallie
  • Aggrecanase molecules
    Publication number: 20040044194
    Abstract: Novel aggrecanase proteins and the nucleotide sequences encoding them as well as processes for producing them are disclosed. Methods of identifying and developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
    Type: Application
    Filed: January 31, 2003
    Publication date: March 4, 2004
    Applicant: Wyeth
    Inventors: Christopher J. Corcoran, Michael J. Agostino, Edward R. Lavallie, Carl R. Flannery, Weilan Zeng, Lisa A. Collins-Racie, Bethany A. Freeman
  • Compositions and methods for detection and treatment of human osteoarthritis
    Patent number: 5427954
    Abstract: The subject invention concerns novel materials and methods for the detection, treatment, and prevention of human osteoarthritis. Specifically, the cleavage site where aggrecanase cleaves aggrecan has been identified. Identification of this site, as well as the nature of the enzyme, facilitates specific treatments which block or diminish the activity of the enzyme. A further aspect of the invention concerns methods for detecting evidence of osteoarthritis.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: June 27, 1995
    Assignee: Shriner's Hospitals for Crippled Children
    Inventors: John D. Sandy, Carl R. Flannery, Peter J. Neame, L. Stefan Lohmander